-
Recent Posts
- December 01 2013 – Human stem cells converted to functional lung cells
- November 30 2013 – Keyhole lung transplant performed on 60-year-old in Chennai
- November 27 2013 – FibroGen Announces Observations of Possible Disease Stabilization and Improvement in Interim Analysis of Phase 2 Study of FG-3019
- November 15 2013 – Enzo Biochem Announces Study in Leading Scientific Journal Linking Idiopathic Pulmonary Fibrosis, a Deadly Human Disease with No Effective Treatment Options, to Presence of a Monkey Virus
- November 10 2013 – Research by Saint Louis University scientists offers way to disrupt fibrosis
Recent Comments
- Fish With Captain Frank on June 20 2012 MicroDose Therapeutx and Moerae Matrix Announce Collaboration to Develop Novel Inhaled Treatment for Idiopathic Pulmonary Fibrosis (IPF)
- Raymond on June 9 2011 – Ascend Trial – Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Johng182 on InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
- Johnf73 on InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
- extreme rush on June 28 2012 Grasping at Straws while Gasping for Air
Archives
Categories
Meta
Monthly Archives: June 2013
June 7 2013 – Genoa, McMaster University reveal findings of GP-101 in pulmonary fibrosis treatment
US-based inhaled medicines provider Genoa Pharmaceuticals in collaboration with McMaster University has demonstrated advantages of the inhaled aerosol pirfenidone (GP-101) in the treatment of pulmonary fibrosis. The findings showed that small inhaled doses yielding high peak, short duration lung pirfenidone … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, NAC, Nintedanib, Pirfenidone, Pulmonary Fibrosis
Leave a comment
May 24 2013 – Reflux Medicine Boosts Survival in Lung Disease
PHILADELPHIA — Survival in idiopathic pulmonary fibrosis (IPF) improved significantly in patients treated with proton pump inhibitors (PPIs), adding to a body of literature supporting PPI benefits in IPF, investigators in a retrospective review concluded. Patients treated with PPIs had … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, NAC, Nintedanib, Pirfenidone, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
May 22 2013 – Promedior Presents Encouraging Results from Clinical Study of PRM-151 in Patients with Idiopathic Pulmonary Fibrosis
LEXINGTON, Mass., May 22, 2013 —Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, unveiled data from a clinical study of PRM-151 in an oral presentation at the 2013 American Thoracic Society (ATS) … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, NAC, Nintedanib, Pirfenidone, Promedior, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
May 21 2013 – Genetic variation among patients with pulmonary fibrosis associated with improved survival
Variation in the gene MUC5B among patients with idiopathic pulmonary fibrosis was associated with improved survival, according to a study published online by JAMA. The study is being released early online to coincide with its presentation at the American Thoracic … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, Medical, NAC, Nintedanib, Pirfenidone, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
May 21 2013 – Race Horses May Hold Key to Cure for Deadly Lung Disease Killing Humans, Horses, Other Domestic Animals
LOUISVILLE, Ky., May 20, 2013 /PRNewswire-USNewswire/ — Researchers from human and veterinary medicine want to know more about the lung disease that is killing horses, including thoroughbred horses and other domestic animals, just as it’s claiming an increasing number of … Continue reading
Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, NAC, Nintedanib, Pirfenidone, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
May 16 2013 – Promedior to Present Clinical Data on Lead Drug Candidate, PRM-151, in Patients with IPF at the ATS 2013 Annual Meeting
LEXINGTON, Mass.–(BUSINESS WIRE)–May 16, 2013– Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, today announced that data from a clinical study of PRM-151 in patients with idiopathic pulmonary fibrosis (IPF) will be … Continue reading
Posted in Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, NAC, Nintedanib, Pirfenidone, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
May 8 2013 US/EU – Idiopathic pulmonary fibrosis drug sales “to rise 86.6%/year to 2017″
The idiopathic pulmonary fibrosis (IPF) therapy market across the US and European Union (EU) will be worth more than $1.1 billion by 2017, and pharma companies could stand to benefit handsomely if they can add to the limited knowledge of … Continue reading
Posted in Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, NAC, Nintedanib, Pirfenidone, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
May 6 2013 – Ambrisentan Fails in Lung Fibrosis
The pulmonary hypertension drug ambrisentan (Letairis) was supposed to tackle one of the root causes of idiopathic pulmonary fibrosis but actually worsened that disease, the ARTEMIS-IPF clinical trial showed. In relatively mild IPF patients, ambrisentan appeared to accelerate disease progression … Continue reading
Posted in Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized
Tagged BIBF 1120, Clinical trial, Esbriet, GERD, Idiopathic Pulmonary Fibrosis, ILD, Intermune, Interstitial Lung Disease, IPF, Lung Transplant, NAC, Nintedanib, Pirfenidone, Pulmonary Fibrosis, www.ipftoday.com
Leave a comment
April 29 2013 – Interventions to Improve Symptoms, Quality of Life in Fibrotic ILD: Do They Work?
Patients with fibrotic interstitial lung diseases (e.g. idiopathic pulmonary fibrosis) have a poor overall prognosis, and there are no therapies proven to halt disease progression or extend life. Further, many of these patients have debilitating symptoms, limited functional capacity, and … Continue reading
April 17 2013 – Study shows TOLLIP gene variant is linked to increased mortality risk in IPF patients
A new study looking at the genomes of more than 1,500 patients with idiopathic pulmonary fibrosis, a rare and devastating lung disease, found multiple genetic associations with the disease, including one gene variant that was linked to an increase in … Continue reading
